

DAFTAR PUSTAKA

- CDC. Fat Soluble Vitamins and Micronutrients: Vitamin D. 2017. Available at https://www.cdc.gov/nutritionreport/99-02/pdf/nr_ch2b.pdf. Cited on Jan 12th, 2018.
- Cho YL, Christensen C, Saunders DE, et al. Combined effects of 1,25 dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. *Cancer Res* 1991; 51: 2848-53.
- Criscitiello, C. et al. (2011) ‘Tamoxifen in early-stage estrogen receptorpositive breast cancer: Overview of clinical use and molecular biomarkers for patient selection’, *OncoTargets and Therapy*, 4, pp. 1–11. doi: 10.2147/OTT.S10155.
- Dyanti GAR., Suariyani NLP. 2016. Faktor-faktor keterlambatan penderita kanker payudara dalam melakukan pemeriksaan awal ke pelayanan kesehatan. *Kemas*. 2016. 11(2)
- Egeland, N. G. et al. (2015) ‘The role of microRNAs as predictors of response to tamoxifen treatment in breast cancer patients’, *International Journal of Molecular Sciences*, 16(10), pp. 24243–24275. doi: 10.3390/ijms161024243.
- El Shorbagy, S. et al. (2017) ‘Prognostic Impact of 25-Hydroxyvitamin D Levels in Egyptian Patients with Breast Cancer’, *Journal of Cancer Science & Therapy*, 09(06), pp. 496–502. doi: 10.4172/1948-5956.1000466.
- Freddie Bray, Global Cancer Statistics 2018 : Globocan Estimate of Incidence and Mortality Worldwide for 36 Cancer in 185 countries. CA : a cancer journal for clinicians.2018
- Gabr, H. and marei, elham (2017) ‘Vitamin D Level in Breast Cancer Premenopausal Patients before and after Adjuvant Therapy’, *Egyptian Journal of Radiation Sciences and Applications*, 0(0), pp. 0–0. doi: 10.21608/ejrsa.2017.1210.1013.
- Gerber Bernd, Freund Mathias, Reimer Toralf. 2010. Recurrent Breast Cancer. *Dtsch Arztebl Int* 2010; 107 (6) : 85-91
- Hari Kanker Sedunia 2019. Available at depkes.go.id/pdf.php?=19020100003. Cite on Sept 11th, 2019
- J Xu, AA Simental, et al. 2017. Vitamin D Pathway in Endocrine-Related Cancer : Literature Review. *Clin Surg*.2017; 2:1518
- Karthikayan A., Sureshkumar S., et al. 2018. Low Serum 25-hydroxy vitamin D levels are associated with aggressive breast cancer variants and

poor prognostic factors in patients with breast carcinoma. *Arch Endocrinol Metab.* 2018;62/4

Kementerian Kesehatan Indonesia.Komite Penanggulangan Kanker Nasional. Panduan penatalaksanaan Kanker Payudara

Kim, H. J. et al. (2014) ‘Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients’, *European Journal of Cancer*. Elsevier Ltd, 50(8), pp. 1403–1411. doi: 10.1016/j.ejca.2014.02.026.

Kim, J. S. et al. (2018) ‘Association between changes in serum 25-hydroxyvitamin D levels and survival in patients with breast cancer receiving neoadjuvant chemotherapy’, *Journal of Breast Cancer*, 21(2), pp. 134–141. doi: 10.4048/jbc.2018.21.2.134.

La Puente-Yague M., Cuadrado-Cenzual M., et al. 2018. Vitamin D : and its role in breast cancer. *Kaohsiung Journal of Medical Sciences*. 2018. 34, 423-427

Lopes Nair, Sousa B., et al. 2010. Alterations in Vitamin D Signalling and Metabolic Pathways in breast cancer progression : a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. *BMC Cancer*. 2010;10:483

Lu, D., Jing, L. and Zhang, S. (2016) ‘Vitamin D receptor polymorphism and breast cancer risk a meta- analysis’, *Medicine (United States)*, 95(18), p. e3535. doi: 10.1097/MD.0000000000003535.

Lundqvist, J., Yde, C. W. and Lykkesfeldt, A. E. (2014) ‘ $1\alpha,25$ -Dihydroxyvitamin D3 inhibits cell growth and NF κ B signaling in tamoxifen-resistant breast cancer cells’, *Steroids*. Elsevier Inc., 85, pp. 30–35. doi: 10.1016/j.steroids.2014.04.001.

Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. *Journal of Cancer* 2010;1:101-7.

Manna, S. and Holz, M. K. (2016) ‘Tamoxifen Action in ER-Negative Breast Cancer’, *Signal Transduction Insights*, 5, p. STI.S29901. doi: 10.4137/sti.s29901.

Murray, A. et al. (2017) ‘Vitamin D receptor as a target for breast cancer therapy’, *Endocrine-Related Cancer*, 24(4), pp. 181–195. doi: 10.1530/ERC-16-0463.

Paduch R, Kandefer-Szerszen M. Vitamin D, tamoxifen and β -estradiol modulate breast cancer cell growth and interleukin-6 and metalloproteinase-2 production in three-dimensional co- culture of tumor cell spheroids with endothelium. *Cell biology and toxicology*. 2005; 21:247- 256.

Pike, A. C. W., A. M. Brzozowski, et al. 1997. *Molecular Basis of Agonism and Antagonism in the Estrogen Receptor*. Nature (London). 389: 753-758.

- Pusat Data dan Informasi Kementerian Kesehatan Indonesia. Situasi Penyakit Kanker Indonesia. Oktober 2016. Available at <http://www.depkes.go.id/resources/download/pusdatin/infodatin/InfoDati n%20Bulan%20Peduli%20Kanker%20Payudara%202016.pdf>. Cited on Sept 10th, 2019.
- Ravid A, Rocker D, Machlenkin A, et al. 1, 25-DihydroxyvitaminD3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. *Cancer Res* 1999; 59: 862-7.
- Richards, S. E., Weierstahl, K. A. and Kelts, J. L. (2015) 'Vitamin D effect on growth and vitamin D metabolizing enzymes in triple-negative breast cancer', *Anticancer Research*, 35(2), pp. 805–810.
- Soljic, M. et al. (2018) 'Prognostic value of Vitamin D receptor and insulin-like growth factor receptor 1 expression in triple-negative breast cancer', *Journal of Clinical Pathology*, 71(1), pp. 34–39. doi: 10.1136/jclinpath-2016-204222.
- Sporn MB, Lippman SM. Agents for Chemoprevention and Their Mechanism of Action. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. *Holland-Frei Cancer Medicine*. 6th edition. Hamilton (ON): BC Decker; 2003.
- Ting HJ, Hsu J, Bao BY, Lee YF. Docetaxel-induced growth inhibition and apoptosis in androgen independent prostatecancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. *Cancer Lett* 2007; 247: 122-9.
- Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R. 1,25-Dihydroxyvitamin D3 and all- trans-retinoic acid sensitizebreast cancer cells to chemotherapy-induced cell death. *Cancer Res* 2000; 60: 2040-8.
- Welsh, J. (1994) 'Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.', *Biochemistry and cell biology = Biochimie et biologie cellulaire*, 72(11–12), pp. 537– 545. doi: 10.1139/o94-072.
- WHO. Breast Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2018. available who.int/cancer/detection/breastcancer/en/index1.html Cited on Sept 7th, 2019.
- Wu Xu, Hu Wei, Lu Lan, et al. 2018. Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment. *Acta Pharmaceutica Sinica B* 2019;9(2):203-219
- Yetkin, D. et al. (2018) 'The Investigation of the Effects of Tamoxifen and Vitamin D Combination on the Expression of P53, Bcl-2 and Bax and Cell Cycle in Mcf-7 Cell Line', *Proceedings*, 2(25), p. 1527. doi: 10.3390/proceedings2251527.